Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
AS Adji, JS Widjaja, BG de Liyis - The Egyptian Heart Journal, 2024 - Springer
Abstract Background Mineralocorticoid receptor antagonists (MRAs) have been shown to
improve outcomes in various populations of heart failure (HF) patients. However, the impact …
improve outcomes in various populations of heart failure (HF) patients. However, the impact …
Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis
Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor
antagonists (MRAs), have been reported to improve clinical prognosis among individuals …
antagonists (MRAs), have been reported to improve clinical prognosis among individuals …
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany
F Kerwagen, C Ohlmeier, T Evers, S Herrmann… - European Journal of …, 2024 - Springer
Purpose Vericiguat reduced clinical endpoints in patients experiencing worsening heart
failure in clinical trials, but its implementation outside trials is unclear. Methods This …
failure in clinical trials, but its implementation outside trials is unclear. Methods This …
Deprescribing strategies in older patients with heart failure
G Tersalvi, V Beltrani, M Peronti, L Furlan, A Foy… - Internal and Emergency …, 2024 - Springer
Older patients with heart failure are particularly vulnerable due to a wide range of associated
comorbidities, disability, and frailty. This population often receives multiple prescriptions …
comorbidities, disability, and frailty. This population often receives multiple prescriptions …
Special focus on the new anti-diabetic drugs
S Agewall - European Heart Journal-Cardiovascular …, 2024 - academic.oup.com
In this issue of the journal, the main focus is on the new diabetes mellitus drugs. Type 2
diabetes mellitus (T2DM) is associated with an increased risk of all-cause mortality. 1 Large …
diabetes mellitus (T2DM) is associated with an increased risk of all-cause mortality. 1 Large …
[PDF][PDF] Mineralokortikoidreceptor-antagonisták alkalmazása a szívelégtelenség kezelésében: irodalmi áttekintés
K Árpád, T Hedvig, N Viktória, S Róbert - Cardiologia Hungarica, 2024 - real-j.mtak.hu
A mineralokortikoidreceptor-antagonista (MRA) szerek randomizált klinikai vizsgálatok
alapján nagyon hatékony terápiás lehetőségnek bizonyultak a csökkent ejekciós frakciójú …
alapján nagyon hatékony terápiás lehetőségnek bizonyultak a csökkent ejekciós frakciójú …
[引用][C] Applying the 'touch‐and‐go'concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management
N Girerd, I Emrich, JP Ferreira - European Journal of Heart …, 2024 - Wiley Online Library
Mineralocorticoid receptor antagonists (MRAs) are pivotal in the management of heart
failure (HF) with reduced ejection fraction (HFrEF), offering robust reductions in mortality and …
failure (HF) with reduced ejection fraction (HFrEF), offering robust reductions in mortality and …